Electromed at H.C. Wainwright conference: growth meets niche opportunity

On Monday, 14 September 2026, Electromed (ELMD) made a presentation at the H.C. Wainwright 28th Annual Global Investment Conference, positioning itself as a rare microcap story. The company is profitable, generates cash, has no debt, and operates a single product category. With trailing 12-month revenue of $75 million, a 78% gross margin, and $20 million in cash reserves, Electromed remains heavily invested in airway clearance therapy for bronchiectasis, a chronic lung disease affecting about 1 million Americans, with only 150,000 currently using airway clearance technology.

The company's direct sales model, payer contracts, and home care focus cover 87% of the U.S. patient population. Electromed's SmartVest, a device employing high-frequency chest wall oscillation, has demonstrated lower antibiotic use, fewer hospitalizations, and fewer emergency room visits among users. Growth plans include adding sales staff, expanding hospital business, developing new products, and investing in reimbursement support.

With a P/E ratio of 20.45 and a PEG ratio of 0.38, Electromed's stock appears undervalued, according to InvestingPro analysis. The company's vertical integration, direct sales approach, and U.S.-manufactured products contribute to its competitive advantage. Electromed's strong performance outpaces the Russell Microcap Index in sales growth, gross profit margin, and operating margin.